protease (NS34A) and an RNA polymerase (NS5B) -are attractive drug targets. In the 2000s, inhibitors of these enzymes and of another nonenzymatic but essential HCV protein (NS5A), referred to as direct acting antivirals (DAAs), emerged as the lead targets for HCV drug development. In late 2011, two NS34A protease inhibitors were approved for human use in combination with PEGylated interferon and ribavirin, raising treatment suc cess to more than 70% for patients with HCV genotype 1 (there are six highly divergent and variable genotypes of the virus).
However, euphoria over this advance was shortlived. Patients with advanced disease were treated but many others were not, owing to the additional, often severe, side effects of this drug combination and the emergence of viral resistance. In the meantime, and continu ing into the present, dozens of new compounds were being tested in the clinic. In 2013, more potent DAAs, in combination with PEGylated interferon and ribavirin, were approved, as was the first alloral regimen, consisting of a NS5B targeting DAA combined with ribavirin alone.
The recent clinical studies [5] [6] [7] [8] [9] [10] [11] present the next wave of interferonfree, alloral, DAA based regimens, which are likely to be approved in the near future for HCV treatment. Without delving into details and trade names, several key points about these trials emerge. First, they include multiple alloral combinations that can achieve success rates of more than 95%. 'Suc cess' for HCV treatment means no detectable virus 12 weeks after stopping treatment. Unlike drug treatments for hepatitis B and HIV, most HCV researchers believe that this endpoint represents a durable cure that lowers the risk of progressive liver disease. Second, these treatments are effective in patients who are in greatest need and are most difficult to treat -those with advanced fibrosis and cirrhosis, those who are coinfected with HIV, and even livertransplant candidates and recipients. Also noteworthy is that the new drug combinations promise shorter treatment times (12 weeks and possibly even less) and minimal side effects; as a result, fewer people are expected to discontinue their treatment.
So from a mystery virus and a 5% treatment success rate, we have come to an era of cure rates of more than 95% (Fig. 1) . Game over, right? Not quite. What about viral resistance to the drugs? With nearly 200 million infected individuals, 6 diverse viral genotypes and around 1 trillion viral variants being gener ated per day per infected person, it is likely that HCV will have some tricks up its sleeve to develop resistance. However, some of the new DAAs, in particular sofosbuvir, which targets the active site of NS5B, have an extremely high barrier to resistance, and there have been only rare glimpses of resistant variants in clinical observations with multiple viral geno types 13 . Combining potent DAAs, each with lower resistance barriers, can still be highly effective at avoiding the buildup of resistance. Nonetheless, resistance will undoubtedly occur and should be taken into account to guide treatment decisions. The current drugs are also less effective against genotype 3 HCV, which is common in South Asia, although pan genotype drugs are in development.
Another barrier is identifying those infected. Most people are unaware of their HCV infection 14 , and only a small minority has been treated 15 . Although some health agen cies have recommended universal screening of highrisk groups, implementing such poli cies is challenging and timeconsuming. And once infected individuals are identified, how will society pay for their treatment? The cur rent price tag for cuttingedge HCV treatment in the United States is more than US$80,000 for a 12week course. Competition among pharmaceutical companies may lower this price, but most people infected with HCV live in countries that cannot afford the new treat ments. Fortunately, there is movement in the pharmaceutical industry to provide for low cost drug production in certain countries, such as Egypt, where an estimated 10% of the pop ulation is infected. Finally, getting rid of the virus does not always erase the risk of future liverrelated problems -patients still need to be monitored routinely for liver function and cancer, particularly those whose infection had led to cirrhosis.
With the new drugs that are in hand or on the horizon, we have the means to eradicate this virus, possibly without needing a vaccine. However, the challenge now is to extend these great medical advances on a national and global scale to those in need -something that has not been terribly effective in the past. We can hope that implementing these transforma tive HCV advances will help to create a model for success, for this and other widespread human diseases. ■ Charles M. Rice 
Quality-control pathway unlocked
A modified ubiquitin protein has been identified by three independent studies as the missing link in a cellular quality-control pathway that is implicated in Parkinson's disease. See Letter p.162 A S A A B E L I OV I C H P arkinson's disease, a progressive neuro degenerative disorder, has long been hypothesized to be caused by defects in organelles called mitochondria, which power mammalian cells through the production of ATP molecules. An accumulation of dys functional mitochondria may lead not only to a cellular energy crisis, but also to excessive production of toxic byproducts. Two enzymes implicated in Parkinson's disease, PINK1 and parkin 1, 2 , are thought to be involved in the disposal of defective mitochondria, but how the two proteins interact has been unclear. A trio of studies (by Kane et al. 3 , writing in the Journal of Cell Biology; by Kazlauskaite et al. 4 , in the Biochemical Journal; and by Koyano et al. 5 , on page 162 of this issue) now report that phosphorylated ubiquitin protein is the link between PINK1 and parkin, provid ing insights into a complex system of parkin regulation.
Kinase enzymes such as PINK1 alter the behaviour of target proteins through the addi tion of phosphate groups, a process called phosphorylation. PINK1 is imported to mito chondria and, in healthy cells, undergoes rapid degradation 6 . However, if mitochondria are defective or damaged (for example by exposure to CCCP, a poison that blocks ATP production), PINK1 accumulates, becoming anchored to the outer mitochondrial mem brane with its kinase domain exposed to the cytoplasm.
Damaged mitochondria also attract par kin, which is otherwise dispersed throughout the cytoplasm in healthy cells 7 . Parkin is a ubiquitin ligase, which adds ubiquitin pro teins (either singly or in polyubiquitin chains) both to itself through autoubiquitination and to nearby target proteins. Ubiquitinated pro teins can serve as a signal to the cell that a cel lular compartment should be degraded, which in damaged mitochondria leads to their timely disposal 7 , a process known as mitophagy. Mutations in either PINK1 or PARKIN that underlie rare familial forms of Parkin son's disease disrupt mitophagy, implicating this cellular pathway in Parkinson's disease 7 . Furthermore, PINK1 mutations impede the recruitment of parkin to damaged mitochon dria, suggesting that the proteins act in a linear pathway. Consistent with a PINK1-parkin qualitycontrol pathway, mutations in pink1 or parkin in fruit flies cause accumula tion of defective mitochondria and cellular degeneration 8, 9 . Initial models proposed that PINK1 phos phorylates and so activates parkin in damaged mitochondria. Although direct phospho rylation of parkin by PINK1 has been docu mented 10 , this modification does not seem to be sufficient for full activation of parkin's ubiq uitinligase activity [3] [4] [5] 10 . In search of a func tional connection between PINK1 and parkin, three groups undertook cellwide protein analyses and biochemical studies, and found the missing link between the two -phospho rylated ubiquitin (phosphoubiquitin).
Each study showed that, in cells in which PINK1 was activated by CCCP treatment, PINK1 phosphorylates ubiquitin at a serine aminoacid residue (serine 65). Strikingly, a corresponding serine65 residue in a ubiqui tinlike domain is the aforementioned target of PINK1 phosphorylation on parkin 10 . Sub sequent analyses by all three groups dem onstrated that modified ubiquitin, in turn, induces parkin activity (Fig. 1) .
Koyano and coworkers found that modi fied ubiquitin alone could not fully activate parkin -complete activation required coin cident modification of parkin's ubiquitinlike domain as well as of ubiquitin, each at their respective serine65 residues. A unique aspect of this group's work is their use of a strain of yeast that harbours a mutant form of ubiquitin lacking the serine65 residue, which cannot be phosphorylated by PINK1. When the authors added human PINK1 and parkin to these cells, they found that parkin was not activated, underscoring the idea of an ordered pathway for mitophagy.
Whereas all three studies implicate phos phorylated ubiquitin as an intermediary in the PINK1-parkin pathway, the role of direct phosphorylation of parkin by PINK1 seems more complex. Koyano and colleagues report that modification of both ubiquitin and parkin at serine65 is necessary for full activation of parkin in cells. But Kane and colleagues found evidence that modification of ubiquitin alone can activate parkin. This discrepancy is likely to relate to the distinct assays used in the stud ies, rather than to a biological difference.
Consistent with phosphoubiquitin's activat ing role, Kane et al. and Koyano et al. found that it binds directly to parkin. Koyano and colleagues took the studies a step further, dem onstrating that phosphoubiquitin can still be used by parkin as a substrate for ubiquitina tion and autoubiquitination. But, surprisingly, the group found that parkin could be activated by phosphoubiquitin that was mutated or modified such that it could not act directly as a substrate in ubiquitination. This implies that phosphoubiquitin binds to and activates parkin separately from its role as a substrate.
Clues as to how this could be achieved might be gleaned from recent crystallographic analyses of parkin 11, 12 . A phosphopeptide binding pocket has been proposed 11 to lie within an inhibitory domain in parkin that, when the protein is inactive, occludes access to its catalytic active site. Kazlauskaite et al. speculate that the active site of parkin could be exposed by conformational changes brought about by the binding of phosphoubiquitin's phosphate group to this inhibitory domain.
Kane and coworkers' data point to another role for phosphoubiquitin -recruiting par kin to the outer membrane of damaged mito chondria. A particularly interesting idea is that such recruitment may generate a positive feedback loop, in which recruited parkin would be predicted to ligate additional phospho ubiquitin to nearby proteins, attracting yet more parkin.
A subset of known parkin substrates, includ ing the proteins mitofusin 2 and Miro, regulate mitochondria 13, 14 , and their ubiquitination by parkin may be required for normal mitophagy. It will be important to determine whether acti vation by phosphoubiquitin affects parkin's target selection, the fate of ubiquitinated tar get proteins, or the structure of polyubiquitin chains formed on targets. Finally, drugs that mimic the effects of phosphoubiquitin may be candidate therapeutics for inherited and sporadic forms of Parkinson's disease. ■ Figure 1 | PINK1 and parkin in mitochondrial quality control. Mitochondrial damage leads to anchoring of the PINK1 enzyme to the outer mitochondrial membrane, with its kinase domain facing the cytoplasm. PINK1 adds a phosphate group (P) to the ubiquitinlike domain (Ubl) of the ubiquitinligase enzyme parkin. Three studies [3] [4] [5] find that PINK1 also phosphorylates the ubiquitin (Ub) protein itself. Phosphorylated ubiquitin directly binds to and activates parkin. Activated parkin ligates ubiquitin and phosphoubiquitin molecules to nearby target proteins, leading to disposal of the damaged mitochondria through mitophagy. 
